A phase II study to evaluate anlotinib plus TQB2450 as adjuvant therapy in patients with esophageal squamous cell carcinoma (ALTER-E005).

被引：0
|
作者：
Guo, Changying
Chen, Shengjia
Ye, Yongqiang
Mao, Wei-Min
机构：
[1] Jiangxi Prov Tumor Hosp, Nanchang, Jiangxi, Peoples R China
[2] Jiujiang 1 Peoples Hosp, Jiujiang, Peoples R China
[3] Ganzhou Canc Hosp, Ganzhou, Peoples R China
[4] Zhejing Canc Hosp, Hangzhou, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS488
引用
收藏
页码：TPS488 / TPS488
页数：1
相关论文
共 50 条
  • [41] A phase II study of chemoradiotherapy in patients with stage II, III esophageal squamous cell carcinoma (ESCC) (JCOG 9906)
    Muro, K.
    Ohtsu, A.
    Ishikura, S.
    Boku, N.
    Takiuchi, H.
    Saito, H.
    Kaneko, K.
    Miyata, Y.
    Komatsu, Y.
    Shirao, K.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [42] Final Results of a Phase II Study of Definitive Chemoradiation Therapy Using S-1 for Esophageal Squamous Cell Carcinoma Patients
    Chen, Y.
    Zhu, Z.
    Zhao, W.
    Li, L.
    Liu, Q.
    Zhang, J.
    Jiang, L.
    Ai, D.
    Zhang, Z.
    Zhao, K.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2019, 105 (01): : S131 - S132
  • [43] Phase II Study of Photodynamic Therapy (PDT) for Local Failure After Chemoradiotherapy (CRT) in Patients With Esophageal Squamous Cell Carcinoma (ESCC)
    Yano, Tomonori
    Muto, Manabu
    Minashi, Keiko
    Kojima, Takashi
    Kaneko, Kazuhiro
    Ohtsu, Atsushi
    GASTROENTEROLOGY, 2010, 138 (05) : S758 - S759
  • [44] Phase 1 Study of Erlotinib Plus Radiation Therapy in Patients With Advanced Cutaneous Squamous Cell Carcinoma
    Heath, C. Hope
    Deep, Nicholas L.
    Nabell, Lisle
    Carroll, William R.
    Desmond, Renee
    Clemons, Lisa
    Spencer, Sharon
    Magnuson, J. Scott
    Rosenthal, Eben L.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2013, 85 (05): : 1275 - 1281
  • [45] First-line benmelstobart plus anlotinib and chemotherapy in advanced or metastatic/recurrent esophageal squamous cell carcinoma: a multi-center phase 2 study
    Li, Ning
    Xia, Jin
    Gao, Xiaohui
    Zhou, Jianwei
    Hong, Yonggui
    Cui, Donghai
    Zhao, Xuesong
    Wu, Tao
    Guo, Yanzhen
    Wang, Junsheng
    Luo, Suxia
    SIGNAL TRANSDUCTION AND TARGETED THERAPY, 2024, 9 (01)
  • [46] Updated results of the phase II ALTER-H004: Anlotinib combined with TACE as adjuvant therapy in hepatocellular carcinoma patients at high risk of recurrence after surgery
    Wu, Zheng
    Wang, Zheng
    Zhang, Lei
    Song, Xiaojing
    Du, Xilin
    Tan, Kai
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [47] Concurrent radiotherapy with gefitinib in elderly patients with esophageal squamous cell carcinoma: Preliminary results of a phase II study
    Xu, Yaping
    Zheng, Yuanda
    Sun, Xiaojiang
    Yu, Xinmin
    Gu, Jialei
    Wu, Wei
    Zhang, Gu
    Hu, Jinlin
    Sun, Wenyong
    Mao, Weimin
    ONCOTARGET, 2015, 6 (35) : 38429 - 38439
  • [48] Concurrent radiotherapy with gefitinib in elderly patients with esophageal squamous cell carcinoma: Preliminary results of a phase II study
    Xu, Yaping
    Zheng, Yuanda
    Yu, Xinmin
    Wu, Wei
    Mao, Weimin
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [49] Phase II study of pembrolizumab after chemoradiotherapy (CRT) as adjuvant therapy for locally advanced esophageal squamous cell carcinoma (LA-ESCC) patients at high risk of recurrence following preoperative CRT plus surgery.
    Hsu, Chih-Hung
    Guo, Jhe-Cyuan
    Huang, Ta-Chen
    Kuo, Hung-Yang
    Lin, Chia-Chi
    Hsu, Feng-Ming
    Cheng, Jason C.
    Huang, Pei-Ming
    Lee, Jang-Ming
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
  • [50] Pembrolizumab plus anlotinib as first-line treatment in patients of CPS≥1 with recurrent or metastatic head and neck squamous-cell carcinoma: A prospective phase II study
    Gui, L.
    He, X.
    Yang, J.
    Liu, P.
    Qin, Y.
    Shi, Y-K.
    ANNALS OF ONCOLOGY, 2022, 33 : S1524 - S1524
12345